Drug Supply Chain Issues More Likely to Result in Shortages in U.S. Than Canada
On Oct. 31, 2024, researchers from the University of Pittsburgh reported results of a study that showed drug-related…
Biotechnology | Chemical | Diagnostics | Disease | Environmental | Life Science News | Nanotechnology | Pharmaceutical | Therapeutics
Nanoplastics can reduce the effectiveness of antibiotics
On Oct. 30, 2024, an international research team led by the University of Bonn reported results of a…
Biotechnology | Diagnostics | Disease | Life Science News | Medicine | Non-Profit Research | Pharmaceutical | Therapeutics
Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies
On Oct. 16, 2024, Sanofi announced it will contribute $18 million to three Historically Black Medical Schools to…
Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion
On Oct. 14, 2024, Lundbeck and Longboard Pharmaceuticals announced an agreement for Lundbeck to acquire Longboard for payment…
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for Treatment of Adults and Adolescents with Hemophilia A or B
On Oct. 11, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved HYMPAVZIâ„¢ (marstacimab-hncq)…
Lilly announced $4.5 billion investment in the Lilly Medicine Foundry – to drive innovation in drug production and medicines for clinical trials
On Oct. 2, 2024, Eli Lilly and Company announced a $4.5 billion investment to create the Lilly Medicine…
Biotechnology | Diagnostics | Life Science News | Oncology | Pharmaceutical | Radiology | Therapeutics
Breast Cancer Mortality Continues Three Decade Decline, but Steeper Increases in Incidence for Women <50
On Oct. 1, 2024, the American Cancer Society (ACS) released Breast Cancer Statistics, 2024, the organization’s biennial update…
Biotechnology | Diagnostics | Infectious Disease | Life Science News | Non-Profit Research | Pharmaceutical | Therapeutics
Large-Scale Study Seeks to Unearth Causes of Persistent Symptoms of Lyme Disease
On Sept. 17, 2024, researchers from Tufts University announced they had received a $20.7 million grant from the…
Novavax 2024-2025 COVID-19 Vaccine Available at Major U.S. Pharmacies
On Sep. 13. 2024, Novavax announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to…
Biotechnology | COVID-19 | Life Science News | Medical Device | Medicine | Pharmaceutical | Therapeutics | Vaccine
Covid-19 pandemic changed scientific publishing
On Sep. 9, 2024, Santo Fortunato, a professor at Luddy School of Informatics, reported that an international research…
Biotechnology | Disease | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine
Emergent BioSolutions’ ACAM2000® Received U.S. FDA Approval for Mpox Indication
On Aug. 29, 2024, Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental Biologics…
Lilly opened state-of-the-art research and development center in the Boston Seaport
On Aug. 13, 2024, Eli Lilly announced the opening of the Lilly Seaport Innovation Center (LSC), a research…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Pharmaceutical | Polio | Vaccine
Novartis, Viatris face lawsuit over ‘HeLa’ cell misuse claims
On Aug. 5, 2024, Novartis and Viatris were named a federal lawsuit in Maryland by the family of…
Paxlovid led to better outcomes in hospitalized COVID cohort than Veklury or both drugs
On Jul. 24, 2024, the University of Hong Kong released a study that showed hospitalized COVID-19 patients treated…
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
On Jul. 3, 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Commission (EC) has approved Dupixent® (dupilumab)…
Biotechnology | Disease | Life Science News | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | Vaccine
Emergent BioSolutions Awarded $250+ Million in Contract to Supply U.S. Government with Four Critical Medical Countermeasure Products
On Jul. 2, 2024, Emergent BioSolutions announced it had received more than $250 millionin contract modifications from the…
Novo Nordisk announced 4.1 billion USD investment to expand US manufacturing capacity
On Jun. 24, 2024, Novo Nordisk announced plans to invest 4.1 billion US dollars to build a second…
U.S. FDA Approved CAPVAXIVEâ„¢ (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVEâ„¢ (Pneumococcal…
Agriculture | Artificial Intelligence | Biology | Biotechnology | CMO | CRO | Life Science News | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
BioMADE to Establish Bioindustrial Manufacturing Infrastructure in Minnesota
On Jun. 13, 2024, BioMADE announced an investment in a state-of-the-art bioindustrial manufacturing infrastructure in Minnesota, following support…
FDA authorized Florida’s Drug Importation Program
On Jan. 5, 2024, the U.S. Food and Drug Administration authorized Florida’s Agency for Health Care Administration’s drug…
Pfizer and BioNTech received Health Canada authorization for XBB.1.5-adapted monovalent COVID-19 vaccine
On Sept. 28, 2023, Pfizer and BioNTech that Health Canada had authorized the companies’ Omicron XBB.1.5-adapted monovalent COVID-19…
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in infants through active immunization of pregnant Individuals
On Aug. 21, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Disease | FDA | Pharmaceutical | Therapeutics | Vaccine
U.S. FDA approved ABRYSVO, Pfizer’s vaccine for prevention of RSV in older adults
On May 31, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory…
Biotechnology | COVID-19 | NIH | Pharmaceutical | Vaccine
SARS-CoV-2 infection weakens immune-cell response to vaccination
On Mar. 20, 2023, NIH scientists announced that the magnitude and quality of a key immune cellï¾’s response…
FDA authorized bivalent Pfizer-BioNTech COVID-19 vaccine as booster dose for certain children 6 months through 4 years of age
On Mar. 14, 2023, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the…
Pfizer announced acquisition of Seattle-based Seagen for $43 billion
On Mar. 13, 2023, Pfizer announced an agreement to acquire Seagen, a global biotechnology company that discovers, develops…
Pfizer’s ZAVZPRET (zavegepant) Migraine Nasal Spray received FDA approval
On Mar. 10, 2023, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved ZAVZPRET (zavegepant),…
Amphastar Pharmaceuticals received FDA approval for Naloxone hydrochloride nasal spray
On Mar. 8, 2023, Amphastar Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had granted approval…
Pfizer and BioNTech announced positive early data from clinical trial of Omicron BA.4/BA.5-adapted bivalent booster
On Oct. 13, 2022, Pfizer and BioNTech announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating…
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada has authorized COMIRNATY Original & Omicron BA.4/BA.5…